Biotechnology sector faces regulatory and funding hurdles in drug development

The biotechnology sector faces significant hurdles in drug development, particularly during Phase I clinical trials. In the United States, administrative and regulatory requirements can delay the initiation of these trials by 18 to 24 months. These delays are often attributed to ambiguous manufacturing requirements and Investigational New Drug (IND) application expectations rather than formal FDA review timelines.

In contrast, Australia’s clinical trial system allows trials to begin sooner and at a lower estimated cost while maintaining safety standards. This efficiency has served as an inspiration for U.S. initiatives like Operation TrialBlazer and the FDA’s proposed Expedited IND pilot, which aim to reform the domestic regulatory pathway.

Beyond regulatory speed, the industry struggles with a gap between scientific discovery and the capital required for validation. The scientific process requires iteration and learning from failure, which often conflicts with the financial sector's demand for rapid returns on investment. Furthermore, competition for federal biomedical research funding is intense; for instance, only 13% of R01-equivalent applications received funding in fiscal year 2025 according to the National Institutes of Health.